Basel, Switzerland, Oct. 16, 2017-Clinerion announces that data integration to its Patient Recruitment System platform can now also process electronic medical records made available by hospitals using the (FHIR) standard. Hospitals using FHIR may now directly exchange data with Patient Recruitment System without the need for additional implementation effort. Fast Healthcare Interoperability Resources (FHIR) is a data exchange standard released by the Health Level Seven International (HL7) health-care standards organization for exchanging healthcare information electronically. FHIR is the latest connector technology which can be accommodated by Clinerion’s Patient Recruitment System. Clinerion’s highly flexible data integration system can handle different data models and standards. This covers i2b2 and more than ten other models used in different hospital information systems worldwide. In addition to FHIR, data exchange with Patient Recruitment System is also possible with the standards HL7, OMOP, and RIM (the last two also released by HL7). Clinerion’s Patient Recruitment System processes electronic patient data at its network of partner hospitals for the provision of its services for clinical trial patient search and identification, data generation for real-world evidence, and market access activities. The patient data are fully anonymized, but Clinerion’s “Anonymized Identification” technology allows authorized hospital staff to re-identify patients on-site for clinical trials. Connection with Patient Recruitment System involves ETL (“exchange, transform, load”) push of anonymized patient data from the hospital’s internal hospital information system to a Patient Recruitment System server installed inside the hospital’s secure IT infrastructure. Patient data security is maintained because the ETL push is fully under the control of the hospital’s IT staff and all patient data stays within the local network of the hospitals. “Patient Recruitment System has always been interoperable with every available electronic health records system currently used-it has been an essential part of our offering,” says Andreas Walter, Clinerion Chief Technology Officer. “The introduction of the FHIR standard to the Clinerion offering simply means we now have standardized processes in place to accommodate FHIR and can therefore react much more quickly than before. With this, we are not only adding additional data input possibilities for standard data models, but also the ability to connect to a large set of HIS systems.” About Clinerion Clinerion enables early patient access to innovative treatments through solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's Patient Recruitment System accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-assisted protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology company headquartered in Switzerland. Clinerion's solutions follow international patient privacy and data security standards. Clinerion website: www.clinerion.com Clinerion’s Patient Recruitment System: www.clinerion.com/index/OverviewOurSolutions/PatientRecruitmentSystem For more information, please contact: Le Vin Chin Head of Marketing and Communications Clinerion Ltd Margarethenstrasse 47, CH-4053 Basel, Switzerland Tel.: +41 61 865 60 54 media@clinerion.com
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.